비근침윤성 방광암의 재발과 진행을 예측하는 임상, 병리적 예후 인자

초록

About 80% of Bladder cancer is non muscle invasive bladder cancer (NMIBC). Despite of appropriate therapy, a lot of NMIBC recur as a superficial tumor or progress to muscle invasive disease. Several studies about prognostic factors of recurrence and progression have reported a single risk factor variously according to each study. These efforts were developed to predict the risk by scoring system and large-scale studies had been conducted. These studies had limitations that their patients did not receive BCG (bacillus Calmette-Guerin) immunotherapy, immediate intravesical chemotherapy, second-look TUR (transurethral resection) in high-risk group. Through studies to date, patients with NMIBC have showed heterogenous prognosis and a more sophisticated scoring system can give personalized treatment and exact prediction.

키워드